Carboplatin-associated ototoxicity in children with retinoblastoma. - Wikidata - wikimedia - TriplyDB

Carboplatin-associated ototoxicity in children with retinoblastoma.

Carboplatin-associated ototoxicity in children with retinoblastoma.

http://www.wikidata.org/entity/Q30513911

about

Different infusion durations for preventing platinum-induced hearing loss in children with cancer Platinum-induced hearing loss after treatment for childhood cancer Different infusion durations for preventing platinum-induced hearing loss in children with cancer Different infusion durations for preventing platinum-induced hearing loss in children with cancer Platinum-induced hearing loss after treatment for childhood cancer Identification of cisplatin-binding proteins using agarose conjugates of platinum compounds Hearing Loss in Patients Who Received Cranial Radiation Therapy for Childhood Cancer Time-frequency analysis of transient-evoked otoacoustic emissions in children exposed to carboplatin chemotherapy Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma.Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.OTOTOXIC EFFECTS OF CARBOPLATIN IN ORGANOTYPIC CULTURES IN CHINCHILLAS AND RATS Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss Blood and marrow transplant clinical trials network state of the Science Symposium 2014 Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.Low-Dose Chemoreduction for Infants Diagnosed with Retinoblastoma before 6 Months of Age.Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.Participation in an occupational therapy referral program for children with retinoblastoma.Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage.Management of retinoblastoma in children: current status.Retinoblastoma: achieving new standards with methods of chemotherapy.Ototoxicity (cochleotoxicity) classifications: A review.Ototoxicity and cancer therapy.Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors.Lessons from Retinoblastoma: Implications for Cancer, Development, Evolution, and Regenerative Medicine.Carboplatin therapeutic monitoring in preterm and full-term neonates.Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis.Long-term auditory complications after childhood cancer: A report from the Swiss Childhood Cancer Survivor Study.Ototoxicity monitoring in children treated with platinum chemotherapy.Lack of vincristine infiltrates in patients with retinoblastoma receiving chemotherapy by peripheral intravenous lines.Targeting Notch signaling as a novel therapy for retinoblastoma.Genetics of cisplatin ototoxicity: confirming the unexplained?Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience.The Potential Benefit of Three vs. Six Cycles of Carboplatin, Etoposide, and Vincristine in Postenucleation High-Risk Patients with IRSS Stage I Retinoblastoma.Long-term follow-up of retinoblastoma survivors: Experience from India.Long-term audiologic follow-up of carboplatin-treated children with retinoblastoma.Ototoxicity in retinoblastoma survivors treated with carboplatin based chemotherapy: A cross-sectional study of 116 patients.Monte Carlo study for designing a dedicated "D"-shaped collimator used in the external beam radiotherapy of retinoblastoma patients.Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre.

P2860

Q24193767-E2250C7B-69DB-45CE-AA0A-FF882E9B7B5B Q24197838-6D5E19D7-D97A-4B0C-AC11-092ED6F794CF Q24202129-F9FD663E-CC43-4A33-852B-77648692A053 Q26470492-500BFF49-3BD8-4098-AAD0-82995410A963 Q26470526-5976DEEF-7045-48F4-97BA-ADFAFA69A827 Q28533598-02F5D763-A246-44E3-A1A5-2867AC29FFE6 Q30368168-2B6827DB-A7D1-42FC-B38E-9762EBE38E26 Q30444977-999BC740-07CD-4B91-89E0-63D829A225AB Q31132958-5A1C5E79-C9B8-40E3-BECA-9496B979F5F0 Q33400825-7E440A98-459E-40AB-8E69-B84383E64351 Q33553382-EDAFC2C5-7E4E-41E1-B7A7-CFC976931D8B Q34829846-8D11A7BC-4094-41B1-A206-0625D11A5254 Q34925061-79E92862-BF6B-437A-AC9D-AEAD1352F11D Q35172741-9E7C88C9-D6F6-4EF2-9F45-5B0B822BC402 Q35591760-4303BBE4-E712-4EBA-B222-E12836C0ED05 Q36035287-1848728A-6660-4495-8ACA-1FC82A563471 Q36843442-0232D9CB-FF2D-4FD2-8252-5CE8AB14057B Q36968257-E42DB0FB-7038-4B1B-B9AC-7A94F3FA11E2 Q37081712-0386BCC3-D5D3-441B-834A-5CE821CE2A6F Q38045274-E7C76278-2AC1-4849-9EA5-5A657AFD4DE4 Q38368017-FD993900-2F39-442A-9AD4-FCEAB3623D1D Q38397827-B22FC4D7-9B91-43B5-B9B8-C80FD47B8532 Q38653146-AFF4F79B-03C1-44AB-B6EF-C743BA6573E0 Q38727368-D1654D42-243E-4010-9EC6-2299FFFAA8E2 Q38738787-28CD5CC8-AA23-43DE-81AB-8D6048E43107 Q38938719-6093CAED-8CE2-4DC5-8FBA-798003CF8D53 Q38978857-4A554198-5157-495D-8252-4EAC322CF345 Q39149552-955194D4-04B8-4D08-B944-00BB5D6E9116 Q39369556-E97A17F5-0A3F-4372-962C-198210C061F4 Q39453840-8B96D419-5CA0-48D5-B5C0-8B0E54724FCD Q41269037-7D3D7387-14B1-4662-9981-72B5550BB9E3 Q42317485-173800C4-53F4-41A4-B96B-40C4A4BAE27E Q46284197-5687DB8F-342A-4A18-A745-51BD1F428697 Q47236877-50EC2969-8A7D-4FB3-B610-41CF471E934D Q47803030-67363686-84D2-46B2-A32D-7D067CC29DE6 Q49305864-5F572B6C-E53F-4438-9E0F-0255ABFF9FFF Q50316767-06AD664D-398E-440B-B958-52AD13DCED5D Q50352441-0196CCD3-0EAC-4805-8320-1A894D213C76 Q50737160-5D011CD3-1487-4962-B35D-1D52EBFEFF42 Q52870608-9358CFDF-39FC-4669-B8A1-F2DCDD7EA239

P2860

Carboplatin-associated ototoxicity in children with retinoblastoma.

http://www.wikidata.org/entity/Q30513911

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Carboplatin-associated ototoxicity in children with retinoblastoma.

@ast

Carboplatin-associated ototoxicity in children with retinoblastoma.

@en

type

label

Carboplatin-associated ototoxicity in children with retinoblastoma.

@ast

Carboplatin-associated ototoxicity in children with retinoblastoma.

@en

prefLabel

Carboplatin-associated ototoxicity in children with retinoblastoma.

@ast

Carboplatin-associated ototoxicity in children with retinoblastoma.

@en

P1433

Q30513911-9EBDF5C2-A099-4A13-A125-3DE6472E2D3F

P1476

Q30513911-A0CF9265-5D80-44C8-9FE6-709E334A033C

P2093

Q30513911-00E90A41-E8C6-48E9-BEA7-4AFFEF90CDFD

Q30513911-0196E3EA-AADB-47AC-9E48-3D290F643D47

Q30513911-1CA2AD6C-C3F1-4A05-84AA-919970442D93

Q30513911-AE899DE9-15A7-48FE-8C07-7A29D284A55F

Q30513911-AF1ECEB9-E596-42F9-BD5C-2179C101B2B8

Q30513911-DC7F97BB-21AC-4301-B9AE-E67E6D4CEDAE

Q30513911-ED8FDB5B-FB42-4EB8-80FA-735F6D988CF6

Q30513911-FDF0F231-505A-48F3-9D06-AD265E7496E2

P2860

Q30513911-1F630ABC-75D1-436D-9FC3-CE4D44D64C81

Q30513911-2D7EF23C-1D4A-482D-91D2-319F762DE241

Q30513911-2DB5675C-0F45-4FE7-8CA2-EACD23B7EB98

Q30513911-30659D7B-1469-4057-8841-5B83B304E911

Q30513911-36C82175-A5F0-4A78-85F1-86398804774F

Q30513911-39037A8A-67C9-4761-913F-46FB3A46AF7C

Q30513911-4DC756AA-8BAF-4558-872C-35DD76968FDD

Q30513911-4EFFE122-7AA9-4432-A618-51197C644461

Q30513911-6CADFB7C-8A68-4A0F-918E-FCEF08564181

Q30513911-83458063-57D0-43D4-BD9B-6BE3318013F5

P304

Q30513911-A16E2529-8E84-4EFF-8F2A-5767A58562C2

P31

Q30513911-A6E25E29-EA21-4E0E-8C85-C2300A80E226

P356

Q30513911-57E0EA69-3673-4D3E-887E-243FEDE328E2

P407

Q30513911-96CB0DC7-CC50-4D0E-B336-CC8924ED76E9

P433

Q30513911-A6D5266D-6CCB-4DDA-B785-57A5DC778B9C

P478

Q30513911-F6DE6EBF-37BD-4972-B38E-3B95C1A8ECEA

P50

Q30513911-EF7A3D3A-9EAA-413A-9347-563D5C54C0EF

P577

Q30513911-00CB914E-5C53-4397-8DA7-4D26B89EEB6B

P698

Q30513911-9D76550F-2FEE-440E-A66E-6EFB23291415

P921

Q30513911-A7EF6D35-E9BE-41E2-92E6-F0AF1F3FAB3D

P932

Q30513911-9DDF7E9A-B1F4-431F-A652-23238001BC00

P356

JCO.2011.36.9744

P1433

Journal of Clinical Oncology

P1476

Carboplatin-associated ototoxicity in children with retinoblastoma

@en

P2093

Amy W Wozniak

http://www.w3.org/2001/XMLSchema#string

Barrett G Haik

http://www.w3.org/2001/XMLSchema#string

Carlos Rodriguez-Galindo

http://www.w3.org/2001/XMLSchema#string

Catherine A Billups

http://www.w3.org/2001/XMLSchema#string

Ibrahim Qaddoumi

http://www.w3.org/2001/XMLSchema#string

Jianrong Wu

http://www.w3.org/2001/XMLSchema#string

Matthew W Wilson

http://www.w3.org/2001/XMLSchema#string

Thomas E Merchant

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of dual sensory loss on auditory localization: implications for intervention.

Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma.

Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study.

Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma.

Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.

Clinical pharmacokinetics and dose optimisation of carboplatin.

Dual sensory loss: overview of problems, visual assessment, and rehabilitation.

Comparison of two methods for carboplatin dosing in children with retinoblastoma.

Developmental pharmacology--drug disposition, action, and therapy in infants and children.

Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group

P304

1034-1041

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.36.9744

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22370329

http://www.w3.org/2001/XMLSchema#string

P921

P932

3341147

http://www.w3.org/2001/XMLSchema#string